Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VVSHIP: H101 + SBRT + PD-1 + Chemo + Targeted Therapy for Unresectable MSS/pMMR CRLM
NCT07381309Phase 2Not yet recruiting
- Sponsor
- Jun Huang Lab
- Start
- Jun 2026
- Primary completion
- Feb 2028
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Oncorine in colorectal cancer (CRC) (2 arms), sponsored by Jun Huang Lab. Primary endpoint: Objective Response Rate at 1 year. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
Oncorine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07381309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07381309.